Skip to main content
BioNTech SE logo

BioNTech SE — Investor Relations & Filings

Ticker · BNTX ISIN · US09075V1026 LEI · 894500UZJ5LG1F8J1U58 US Manufacturing
Open in API
Filings indexed 529 across all filing types
Latest filing 2026-06-08 Transaction in Own Shar…
Country DE Germany
Listing US BNTX

About BioNTech SE

https://www.biontech.com/

BioNTech SE is a global biotechnology company pioneering novel therapies for cancer and infectious diseases. The company leverages its deep expertise in immunology to develop a diverse portfolio of therapeutic platforms. Its oncology pipeline includes mRNA-based cancer immunotherapies, next-generation immunomodulators, and targeted therapies, with a strategy focused on creating synergistic combinations. In infectious diseases, BioNTech applies its proprietary mRNA technology to develop vaccines, most notably co-developing the first authorized mRNA-based vaccine for COVID-19. The company's core mission is to translate scientific research into innovative treatments that harness the power of the immune system to improve or establish new standards of care for patients globally.

Recent filings

Filing Released Lang Actions
6-K
Transaction in Own Shares Classification · 85% confidence The document is a Form 6-K (a regulatory filing) by BioNTech SE announcing an update to its share repurchase program and attached Exhibit 99.1 discloses the share buyback details. This falls squarely under the category for company transactions in its own shares (share repurchase).
2026-06-08 English
6-K
Regulatory Filings Classification · 87% confidence The document is an SEC Form 6-K, a current report by a foreign private issuer disclosing interim clinical trial data via an attached press release. It is a regulatory filing that does not fit into other specific report types (e.g., AGM materials, financial reports, management changes). Thus it falls under the general Regulatory Filings category (RNS).
2026-06-01 English
6-K
Regulatory Filings Classification · 85% confidence The document is a Form 6-K report by a foreign private issuer (BioNTech SE) filed pursuant to the Exchange Act, notifying the SEC and investors of an upcoming presentation at ASCO and attaching a press release as Exhibit 99.1. It contains no substantive financial statements or management discussion; it is a routine regulatory submission. Under our taxonomy, Form 6-K filings and similar regulatory notices default to "Regulatory Filings" (RNS).
2026-05-22 English
6-K
Report Publication Announcement Classification · 85% confidence The document is a Form 6-K cover letter (under 2,000 characters) announcing that the press release, AGM presentation, and voting results are attached as exhibits. It does not contain the actual financial data or AGM materials but simply publishes them, fitting the “Report Publication Announcement” pattern rather than the full report or AGM materials themselves. Under the menu-vs-meal rule, this is an RPA.
2026-05-15 English
6-K - BioNTech SE (0001776985) (Filer)
Transaction in Own Shares Classification · 91% confidence The document is a Form 6-K (regulatory filing by a foreign private issuer) announcing that BioNTech SE has authorized a new ADS repurchase program of up to $1.0 billion. This fits the definition of a share repurchase/own-share transaction. Therefore, the appropriate classification is Transaction in Own Shares (POS).
2026-05-07 English
6-K - BioNTech SE (0001776985) (Filer)
Report Publication Announcement Classification · 75% confidence The document is a Form 6-K submitted by a foreign private issuer to the SEC, providing notice that its interim condensed consolidated financial statements and operating review are attached as Exhibit 99.1. The text itself is short (≈2,083 characters) and simply announces the availability and filing of the quarterly report rather than containing substantive financial statements within the body. Under the “menu vs meal” rule, this is an announcement of a report publication (the quarterly report is the “meal,” Exhibit 99.1). Therefore, it is classified as a Report Publication Announcement (RPA).
2026-05-05 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.